Interview with the Innovators

Helping the patient’s caregiver understand their role in the NSCLC patient’s journey
Addressing common questions from NSCLC patients and their caregivers
Providing psychosocial support and counseling for NSCLC patients and their family
Educating patients about cancer- and treatment-related side effect management
Identification of new actionable targets and driver mutations have revolutionized the treatment of NSCLC
Waiting for biomarker test results ensures the best outcomes in NSCLC.
Describing the road map of the cancer care journey in NSCLC.
Nephrectomy is often the initial treatment for renal-cell cancer (RCC), but systemic therapy is frequently required for advanced RCC. Single-agent targeted therapies are only somewhat effective, which led to the development of immunotherapies and combination therapies (which include immunotherapies). Laura Wood, RN, MSN, OCN, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss the clinical advantages of combination therapies in patients with advanced RCC.
Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their roles and responsibilities within their academic oncology centers as valuable members of a multidisciplinary team that helps patients successfully navigate the spectrum of patient care. They also detail how they apply the principles of patient-centered care to improve outcomes for patients.
The use of targeted agents and immunotherapy has transformed the treatment of NSCLC
Page 1 of 3
Results 1 - 10 of 24